Our meta-analysis reported that patients with NSCLC treated with PD-1/PD-L1 inhibitors had higher QOL and fewer adverse symptoms than those with standard chemotherapy, indicating that early social, psychological, and spiritual support can improve the quality of life. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.